Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces carcinoma cell death through the extrinsic pathway of apoptosis. Preclinical trials of gene therapy have been conducted using viral transfer of the TRAIL transgene into prostate, bladder, breast, kidney, liver, non-small cell lung cancer and also glioblastoma cells. Experiments in vitro demonstrated the extensive apoptosis of target cells as well as frequent disease regression or remission. TRAIL transfer did not show any side effects, opposite to chemotherapy. Encouraging results of TRAIL-related gene therapy were observed in rheumatoid arthritis and type 1 diabetes. Adenoviral vectors (AdV) encoding TRAIL are the most promising tool in anti-tumor therapy. They have undergone numerous modifications by increasing transfection efficiency and transgene expression in target cells. However, only one clinical phase I trial has been performed. AdV encoding the TRAIL transgene caused local inflammation and apoptosis in patients with prostate cancer.

References

• 1. Almasan A., Ashkenazi A.: Apo2L/TRAIL: apoptosis signaling,biology, and potential for cancer therapy. Cytokine Growth FactorRev., 2003; 14: 337-348
  Google Scholar
• 2. Armeanu S., Lauer U.M., Smirnow I., Schenk M., Weiss T.S., GregorM., Bitzer M.: Adenoviral gene transfer of tumor necrosis factor-relatedapoptosis-inducing ligand overcomes an impaired responseof hepatoma cells but causes severe apoptosis in primary humanhepatocytes. Cancer Res., 2003; 63: 2369-2372
  Google Scholar
• 3. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., MarstersS.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForgeL., Koumenis I.L., Lewis D., Harris L., Bussiere J. i wsp.: Safety andantitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest.,1999; 104: 155-162
  Google Scholar
• 4. Attar R., Sajjad F., Qureshi M.Z., Tahir F., Hussain E., Fayyaz S.,Farooqi A.A.: TRAIL based therapy: overview of mesenchymal stemcell based delivery and miRNA controlled expression of TRAIL. AsianPac. J. Cancer Prev., 2014; 15: 6495-6497
  Google Scholar
• 5. ClinicalTrials.gov. A service of the U.S. National Institutes of Health.https://clinicaltrials.gov/ct2/results?term=%22trail%22&Search=Search(28.10.2014)
  Google Scholar
• 6. Dirice E., Sanlioglu A.D., Kahraman S., Ozturk S., Balci M.K., OmerA., Griffith T.S., Sanlioglu S.: Adenovirus-mediated TRAIL gene (Ad-5hTRAIL) delivery into pancreatic islets prolongs normoglycemiain streptozotocin-induced diabetic rats. Hum. Gene Ther., 2009; 20:1177-1189
  Google Scholar
• 7. Escors D., Breckpot K.: Lentiviral vectors in gene therapy: theircurrent status and future potential. Arch. Immunol. Ther. Exp.,2010; 58: 107-119
  Google Scholar
• 8. Giacca M.: Gene therapy., Springer-Verlag Milan 2010
  Google Scholar
• 9. Griffith T.S., Anderson R.D., Davidson B.L., Williams R.D., RatliffT.L.: Adenoviral-mediated transfer of the TNF-related apoptosis–inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis.J. Immunol., 2000; 165: 2886-2894
  Google Scholar
• 10. Griffith T.S., Broghammer E.L.: Suppression of tumor growthfollowing intralesional therapy with TRAIL recombinant adenovirus.Mol. Ther., 2001; 4: 257-266
  Google Scholar
• 11. Gromadzka A., Kubiczak M., Jankowska A.: Terapia genowa i jejzastosowanie w leczeniu nowotworów ginekologicznych. Ginekol.Pol., 2010; 81: 50-54
  Google Scholar
• 12. Gura T.: How TRAIL kills cancer cells, but not normal cells. Science,1997; 277: 768
  Google Scholar
• 13. Holoch P.A., Griffith T.S.: TNF-related apoptosis-inducing ligand(TRAIL): a new path to anti-cancer therapies. Eur. J. Pharmacol.,2009; 625: 63-72
  Google Scholar
• 14. Huang X., Lin T., Gu J., Zhang L., Roth J.A., Stephens L.C., Yu Y., LiuJ., Fang B.: Combined TRAIL and Bax gene therapy prolonged survivalin mice with ovarian cancer xenograft. Gene Ther., 2002; 9: 1379-1386
  Google Scholar
• 15. Jacob D., Bahra M., Schumacher G., Neuhaus P., Fang B.: Genetherapy in colon cancer cells with a fiber-modified adenovectorexpressing the TRAIL gene driven by the hTERT promoter. AnticancerRes., 2004; 24: 3075-3079
  Google Scholar
• 16. Johnstone R.W., Frew A.J., Smyth M.J.: The TRAIL apoptotic pathwayin cancer onset, progression and therapy. Nat. Rev. Cancer,2008; 8: 782-798
  Google Scholar
• 17. Kagawa S., He C., Gu J., Koch P., Rha S,J., Roth J.A., Curley S.A.,Stephens L.C., Fang B.: Antitumor activity and bystander effects ofthe tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)gene. Cancer Res., 2001; 61: 3330-3338
  Google Scholar
• 18. Kamieniarz K., Goździcka-Józefiak A.: Zastosowanie AAV jakowektorów w terapii genowej. Biotechnologia, 2005; 1: 79-94
  Google Scholar
• 19. Kang S., Park E.J., Joe Y., Seo E., Park M.K., Seo S.Y., Chung H.Y.,Yoo Y.H., Kim D.K., Lee H.J.: Systemic delivery of TNF-related apoptosis-inducingligand (TRAIL) elevates levels of tissue inhibitor ofmetalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobesediabetic mice. Endocrinology, 2010; 151: 5638-5646
  Google Scholar
• 20. Karra D., Dahm R.: Transfection techniques for neuronal cells.J. Neurosci., 2010; 30: 6171-6177
  Google Scholar
• 21. Keane M.M., Ettenberg S.A., Nau M.M., Russel E.K., LipkowitzS.: Chemotherapy augments TRAIL-induced apoptosis in brest celllines. Cancer Res., 1999; 59: 734-741
  Google Scholar
• 22. Kelley S.K., Harris L.A., Xie D., Deforge L., Totpal K., Bussiere J.,Fox J.A.: Preclinical studies to predict the disposition of Apo2L/tumornecrosis factor-related apoptosis-inducing ligand in humans:characterization of in vivo efficacy, pharmacokinetics, and safety. J.Pharmacol. Exp. Ther., 2001; 299: 31-38
  Google Scholar
• 23. Kim K.U., Seo S.Y., Heo K.Y., Yoo Y.H., Kim H.J., Lee H.S., ChoiS.S., Hwang T.H., Lee H.J.: Antitumor activity of TRAIL recombinantadenovirus in human malignant glioma cells. J. Korean Med. Sci.,2005; 20: 1046-1052
  Google Scholar
• 24. Kim Y.I., Ahn B.C., Ronald J.A., Katzenberg R., Singh A., PaulmuruganR., Ray S., Gambhir S.S., Hofmann L.V.: Intratumoral versusintravenous gene therapy using a transcriptionally targeted viralvector in an orthotopic hepatocellular carcinoma rat model. J. Vasc.Interv. Radiol., 2012; 23: 704-711
  Google Scholar
• 25. Kock N., Kasmieh R., Weissleder R., Shah K.: Tumor therapymediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia,2007; 9: 435-442
  Google Scholar
• 26. Kopiński P., Chorostowska-Wynimko J., Dyczek A., Giżycka A.:Apoptoza limfocytów pęcherzykowych. Część 1 — szlaki apoptozylimfocytów. Pneumonol. Alergol. Pol., 2014; 82: 170-182
  Google Scholar
• 27. Kruyt F.A.: TRAIL and cancer therapy. Cancer Lett., 2008; 263: 14-25
  Google Scholar
• 28. Kwon I., Schaffer D.V.: Designer gene delivery vectors: molecularengineering and evolution of adeno-associated viral vectors forenhanced gene transfer. Pharm. Res., 2008; 25: 489-499
  Google Scholar
• 29. Li F., Guo Y., Han L., Duan Y., Fang F., Niu S., Ba Q., Zhu H., KongF., Lin C., Wen X.: In vitro and in vivo growth inhibition of drug-resistantovarian carcinoma cells using a combination of cisplatin anda TRAIL-encoding retrovirus. Oncol. Lett., 2012; 4: 1254-1258
  Google Scholar
• 30. Ma H., Liu Y., Liu S., Xu R., Zheng D.: Oral adeno-associated virus–sTRAIL gene therapy suppresses human hepatocellular carcinomagrowth in mice. Hepatology, 2005; 42: 1355-1363
  Google Scholar
• 31. Manzo F., Nebbioso A., Miceli M., Conte M., De Bellis F., CarafaV., Franci G., Tambaro F.P., Altucci L.: TNF-related apoptosis-inducingligand: signalling of a ‘smart’ molecule. Int. J. Biochem. CellBiol., 2009; 41: 460-466
  Google Scholar
• 32. Mao L., Yang C., Li L., Nai L., Fan L., Wang J., Li W., Wen R., ChenJ., Zheng J.: Replication-competent adenovirus expressing TRAILsynergistically potentiates the antitumor effect of gemcitabine inbladder cancer cells. Tumour Biol., 2014; 35: 5937-5944
  Google Scholar
• 33. Matsubara H., Mizutani Y., Hongo F., Nakanishi H., Kimura Y.,Ushijima S., Kawauchi A., Tamura T., Sakata T., Miki T.: Gene therapywith TRAIL against renal cell carcinoma. Mol. Cancer Ther.,2006; 5: 2165-2171
  Google Scholar
• 34. Mérino D., Lalaoui N., Morizot A., Solary E., Micheau O.: TRAILin cancer therapy: present and future challenges. Expert Opin. Ther.Targets, 2007; 11: 1299-1314
  Google Scholar
• 35. Mohr A., Henderson G., Dudus L., Herr I., Kuerschner T., DebatinK.M., Weiher H., Fisher K.J., Zwacka R.M.: AAV-encoded expressionof TRAIL in experimental human colorectal cancer leads to tumorregression. Gene Ther., 2004; 11: 534-543
  Google Scholar
• 36. Norris J.S., Hyer M.L., Voelkel-Johnson C., Lowe S.L., RubinchikS., Dong J.Y.: The use of Fas Ligand, TRAIL and Bax in gene therapyof prostate cancer. Curr. Gene Ther., 2001; 1: 123-136
  Google Scholar
• 37. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A.,Ashkenazi A.: Induction of apoptosis by Apo-2 ligand, a new memberof the tumor necrosis factor cytokine family. J. Biol. Chem., 1996;271: 12687-12690
  Google Scholar
• 38. Przybylski G., Wielikdzień J., Kopiński P.: Mechanizmy zaprogramowanejśmierci efektorowych limfocytów T. Postępy Hig. Med.Dośw., 2013; 67: 1374-1390
  Google Scholar
• 39. Rutkowski A., Jaźwa A., Józkowicz A., Dulak J.: Wektory AAVw terapii genowej. Biotechnologia, 2007; 3: 33-44
  Google Scholar
• 40. Rzońca S., Małecki M.: Proapoptotyczna terapia genowa a wrażliwośćnowotworów na chemioterapię. Współcz. Onkol., 2009; 13: 61-65
  Google Scholar
• 41. Secchiero P., Candido R., Corallini F., Zacchigna S., Toffoli B.,Rimondi E., Fabris B., Giacca M., Zauli G.: Systemic tumor necrosisfactor-related apoptosis-inducing ligand delivery shows antiatheroscleroticactivity in apolipoprotein E-null diabetic mice. Circulation,2006; 114: 1522-1530
  Google Scholar
• 42. Shah K., Tung C.H., Breakefield X.O., Weissleder R.: In vivo imagingof S-TRAIL- mediated tumor regression and apoptosis. Mol.Ther., 2005; 11: 926-931
  Google Scholar
• 43. Shi J., Zheng D., Liu Y., Sham M.H., Tam P., Farzaneh F., Xu R.:Overexpression of soluble TRAIL induces apoptosis in human lungadenocarcinoma and inhibits growth of tumor xenografts in nudemice. Cancer Res., 2005; 65: 1687-1692
  Google Scholar
• 44. Skubis-Zegadło J., Stachurska A., Małecki M.: Vectorology ofadeno-associated viruses (AAV). Dev. Period Med., 2013; 17: 202-206
  Google Scholar
• 45. Stańczyk M., Majsterek I.: Apoptoza – cel ukierunkowanej terapiiprzeciwnowotworowej. Postępy Biol. Kom., 2008; 35: 467-484
  Google Scholar
• 46. Stępień A., Izdebska M., Grzanka A.: Rodzaje śmierci komórki.Postępy Hig. Med. Dośw., 2007; 61: 420-428
  Google Scholar
• 47. Stopa M., Dulak J., Józkowicz A.:. Najważniejsze cechy wektorówadenowirusowych Biotechnologia, 2007; 3: 22-32
  Google Scholar
• 48. Stopa M., Dulak J., Józkowicz A.: Optymalizacja warunków transdukcjiwybranych linii komórkowych przy użyciu wektorów adenowirusowychpierwszej generacji. Biotechnologia, 2007; 3: 123-140
  Google Scholar
• 49. Suliman A., Lam A., Datta R., Srivastava R.K.: Intracellular mechanismsof TRAIL: apoptosis through mitochondrial-dependent and-independent pathways. Oncogene, 2001; 20: 2122-2133
  Google Scholar
• 50. Suzuki H., Hotta T., Koyama T., Komagata M., Imakiire A., YanaseN., Yoshimoto T., Mizuguchi J.: Retrovirus-mediated transduction ofTRAIL and chemotherapeutic agents co-operatively induce apoptoticcell death in both sarcoma and myeloma cells. Anticancer Res.,2003; 23: 3247-3253
  Google Scholar
• 51. Szala S.: Założenia terapii genowej. W: Terapia Genowa, red.S. Szala; Wydawnictwo Naukowe PWN, Warszawa, 2003, str. 1-34
  Google Scholar
• 52. Szliszka E., Zydowicz G., Mizgala E., Krol W.: Artepillin C (3,5-diprenyl-4-hydroxycinnamicacid) sensitizes LNCaP prostate cancercells to TRAIL-induced apoptosis. Int. J. Oncol., 2012; 41: 818-828
  Google Scholar
• 53. Śliwińska-Hill U., Trocha J.: Najnowsze terapie przeciwnowotworowe.Post. Farm., 2011; 1: 14-18
  Google Scholar
• 54. Terzioglu E., Bisgin A., Sanlioglu A.D., Ulker M., Yazisiz V., TuzunerS., Sanlioglu S.: Concurrent gene therapy strategies effectivelydestroy synoviocytes of patients with rheumatoid arthritis. Rheumatology,2007; 46: 783-789
  Google Scholar
• 55. VanOosten R.L., Griffith T.S.: Activation of tumor-specific CD8+T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotidecombination therapy. Cancer Res., 2007; 67: 11980-11990
  Google Scholar
• 56. Walther W., Stein U.: Viral vectors for gene transfer: a reviewof their use in the treatment of human diseases. Drugs, 2000; 60:249-271
  Google Scholar
• 57. Wang S.B., Tan Y., Lei W., Wang Y.G., Zhou X.M., Jia X.Y., ZhangK.J., Chu L., Liu X.Y., Qian W.B.: Complete eradication of xenografthepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD–Smac gene with broad antitumor effect. Hum. Gene Ther., 2012;23: 992-1002
  Google Scholar
• 58. Wang Y., Huang F., Cai H., Zhong S., Liu X., Tan W.S.: Potent antitumoreffect of TRAIL mediated by a novel adeno-associated viralvector targeting to telomerase activity for human hepatocellularcarcinoma. J. Gene Med., 2008; 10: 518-526
  Google Scholar
• 59. Wang Y., Ma L., Wang S., Bao Y., Ni C., Guan N., Zhao J., Fan X.:Assessment of CAR- or CD46-dependent adenoviral vector-mediatedTRAIL gene therapy in clinical adenocarcinoma lung cancer cells.Oncology, 2009; 77: 366-377
  Google Scholar
• 60. Wang Y.G., Wang J.H., Zhang Y.H., Gu Q., Liu X.Y.: Antitumoreffect of a novel adeno-associated virus vector targeting to telomeraseactivity in tumor cells. Acta Biochim. Biophys. Sin., 2004;36: 492-500
  Google Scholar
• 61. Wenger T., Mattern J., Haas T.L., Sprick M.R., Walczak H., DebatinK.M., Büchler M.W., Herr I.: Apoptosis mediated by lentiviral TRAILtransfer involves transduction-dependent and -independent effects.Cancer Gene Ther., 2007; 14: 316-326
  Google Scholar
• 62. Wiley S.R., Schooley K., Smolak P.J., Din W.S, Huang C.P., NichollJ.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., Goodwin R.G.:Identification and characterization of a new member of the TNF familythat induces apoptosis. Immunity, 1995; 3: 673-682
  Google Scholar
• 63. Wohlfahrt M.E., Beard B.C., Lieber A., Kiem H.P.: A capsid-modified,conditionally replicating oncolytic adenovirus vector expressingTRAIL Leads to enhanced cancer cell killing in human glioblastomamodels. Cancer Res., 2007; 67: 8783-8790
  Google Scholar
• 64. Wu G.S.: TRAIL as a target in anti-cancer therapy. Cancer Lett.,2009; 285: 1-5
  Google Scholar
• 65. Wu X.X., Ogawa O., Kakehi Y.: TRAIL and chemotherapeuticdrugs in cancer therapy. Vitam. Horm., 2004; 67: 365-383
  Google Scholar
• 66. Wu Z., Asokan A., Samulski R.J.: Adeno-associated virus serotypes:vector toolkit for human gene therapy. Mol. Ther., 2006; 14:316-327
  Google Scholar
• 67. Xu F., Tian Y., Huang Y., Zhang L.L., Guo Z.Z., Huang J.J., Lin T.Y.:EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL–induced apoptosis. Chin. J. Cancer, 2011; 30: 701-711
  Google Scholar
• 68. Yao Q., Wang S., Gambotto A., Glorioso J.C., Evans C.H., RobbinsP.D., Ghivizzani S.C., Oligino T.J.: Intra-articular adenoviral-mediatedgene transfer of trail induces apoptosis of arthritic rabbit synovium.Gene Ther., 2003; 10: 1055-1060
  Google Scholar
• 69. Yi Y., Noh M.J., Lee K.H.: Current advances in retroviral genetherapy. Curr. Gene Ther., 2011; 11: 218-228
  Google Scholar
• 70. Yoo J., Choi S., Hwang K.S., Cho W.K., Jung C.R., Kwon S.T., ImD.S.: Adeno-associated virus-mediated gene transfer of a secretedform of TRAIL inhibits tumor growth and occurrence in an experimentaltumor model. J. Gene Med., 2006; 8: 163-174
  Google Scholar
• 71. Young L.S., Searle P.F., Onion D., Mautner V.: Viral gene therapystrategies: from basic science to clinical application. J. Pathol.,2006; 208: 299-318
  Google Scholar
• 72. Yuan X.F., Peng H.W., Ding Y.H., Yan C.H., Zhang Y.J., Yang M.,Xiong D.S.: Gene therapy in B-NHL cell line using adenovirus-mediatedtransfer of secretable trimeric TRAIL gene expression drivenby CD20 promoter. Exp. Hematol., 2013; 41: 221-230
  Google Scholar
• 73. Zhang H., Sui A., Wang Z., Liu S., Yao R.: Adenovirus-mediatedTRAIL expression and downregulation of Bcl-2 expression suppressesnon-small cell lung cancer growth in vitro and in vivo. Int. J. Mol.Med., 2012; 30: 358-364
  Google Scholar

Full text